Researchers are investigating whether a common cholesterol drug could be repurposed to treat HPV-positive cervical cancer.

and are executed largely via the E6 and E7 viral oncoproteins carried in the genomes of oncogenic HPV strains. The E6 viral oncoprotein binds to p53, resulting in ubiquitination of the cellular ...

Thus, boosting anti-HPV T cells can further protect the skin ... we studied the interaction between the virus and the main mutation caused by UV, p53 mutation, using experimental models and ...

A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled "Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells.

HPV variants and viral load. Persistent vs transient infection. Host factors: HLA Class II and p53 polymorphisms; nutrition.